Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lala M Dunbar

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The American Journal of the Medical Sciences|December 13, 2003
Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistanceLala M Dunbar
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|October 28, 2017
In responseEdward A Panacek, Lala M Dunbar
Therapeutics and Clinical Risk Management|August 30, 2008
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)Lala M Dunbar, Derek M Tang, Robert M Manausa
Antimicrobial Agents and Chemotherapy|May 4, 2011
Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trialLala M Dunbar, Joe Milata, Ty McClure, et al.
BMC Infectious Diseases|June 2, 2005
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter studyCharles M Fogarty, Tushar C Patel, Lala M Dunbar, et al.
Current Medical Research and Opinion|May 4, 2004
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogensLala M Dunbar, Mohammed M Khashab, James B Kahn, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infectionsMartin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyMartin E Stryjewski, Vivian H Chu, William D O'Riordan, et al.
Annals of Emergency Medicine|February 27, 2004
Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with woundsDavid A Talan, Fredrick M Abrahamian, Gregory J Moran, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The American Journal of the Medical Sciences|December 13, 2003
Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistanceLala M Dunbar
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|October 28, 2017
In responseEdward A Panacek, Lala M Dunbar
Therapeutics and Clinical Risk Management|August 30, 2008
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)Lala M Dunbar, Derek M Tang, Robert M Manausa
Antimicrobial Agents and Chemotherapy|May 4, 2011
Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trialLala M Dunbar, Joe Milata, Ty McClure, et al.
BMC Infectious Diseases|June 2, 2005
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter studyCharles M Fogarty, Tushar C Patel, Lala M Dunbar, et al.
Current Medical Research and Opinion|May 4, 2004
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogensLala M Dunbar, Mohammed M Khashab, James B Kahn, et al.
The Journal of Antimicrobial Chemotherapy|March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infectionsMartin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyMartin E Stryjewski, Vivian H Chu, William D O'Riordan, et al.
Annals of Emergency Medicine|February 27, 2004
Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with woundsDavid A Talan, Fredrick M Abrahamian, Gregory J Moran, et al.
Pageof 2